NEWS

Life Sciences Venture Fund aMoon Invests $5 Million in Cancer Drug Company

December 24, 2019

Israel-based life sciences, healthcare, and technology venture capital firm aMoon, together with an unnamed private investor, invested $5 million in cancer drug startup NanoGhosts, aMoon told Calcalist. This is NanoGhosts’s first investment.

Read More

Seer Announces $55 Million in Series D Equity Financing Bringing in New Investors aMoon Fund and T. Rowe Price Funds

December 19, 2019

Capital will enable continued advancement of novel Proteograph™ platform and commercialization of first-in-class proteomics products

Read More

Newly Merged Voice Analysis Startups Healthymize and Beyond Verbal Raise $9 Million

December 10, 2019

The new entity, Vocalis Health, will develop technology for the voice-based analysis and detection of health issues such as heart and respiratory conditions and depression

Read More

Steven Mnuchin, Israeli Health Officials Discuss Establishment of Israeli FDA Branch

October 29, 2019

The FDA, which approves all medical devices and formulations in the U.S., has very few branches outside of the U.S.

Read More

aMoon invests in $80m Adicet Bio financing round

October 3, 2019

Based on technology developed by the Technion’s Prof. Yoram Reiter, Adicet Bio is developing allogeneic cell therapies for cancer using innovative gamma delta T cells.

Read More

MDClone, Developer of First Healthcare Synthetic Data Engine, Raises $26 Million

August 22, 2019

aMoon Leads New Investment Round with Participation from OrbiMed and Lightspeed Venture Partners.

Read More

Israel’s 10 ‘Hottest’ Startups In 2019, According to WIRED Magazine

August 21, 2019

Tel Aviv – has “the highest number of startups per capita in the world…with more than 6,000, of which 18 are unicorns…more than 100 venture capital funds, plus hundreds of accelerators and co-working places.”

Read More

Nobio gets FDA approval for anti-bacterial dental fillings

August 5, 2019

TEL AVIV (Reuters) – Israel’s Nobio Ltd said on Monday it received approval from the U.S. Food and Drug Administration to market its anti-bacterial composite designed to remain in the teeth for decades.

Read More

Can This Ancient Greek Medicine Cure Humanity?

July 26, 2019

There’s fresh interest in a fabled shrub on the Aegean island of Chios.

Read More

Marius Nacht Buys Controlling Stake in Universal Flu Vaccine Developer BiondVax

July 17, 2019

Based in Jerusalem, Nasdaq-listed BiondVax develops a universal flu vaccine, currently in advanced clinical trials

Read More

Combining machine learning tools for medical imaging with genetic sequencing nets Sophia Genetics $110M

October 1, 2020

With the closure of its sixth venture capital round, the Swiss health data firm Sophia Genetics added another $110 million to its coffers in a series F financing led by aMoon and Hitachi Ventures.

Read More

Venture capitalists find more to Israel than Zionism

September 30, 2020

Not all olim arrive in Israel to serve in the IDF or go to university. In the case of two aMoon executives, coming to Israel was a way to advance their careers in venture capital health investments while also reaching the goal of living in the Jewish state.

Read More

Adicet Announces Completion of Merger with resTORbio

September 15, 2020

Adicet Bio, Inc., a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced the completion of its previously announced merger with resTORbio, Inc

Read More

Seer Announces Spin Out of PrognomIQ with $55 Million Initial Financing

September 15, 2020

Seer, Inc., an aMoon2 portfolio company focused on enabling exceptional scientific outcomes through the power of unbiased, deep, rapid and scalable proteomics information, today announced that it has spun out and completed the initial financing of $55M for a newly formed healthcare company, PrognomIQ, Inc.

Read More

MiNA Therapeutics Secures £23 Million Series A Financing to Advance First-in-Class Activating RNA-Based Therapeutics

September 10, 2020

MiNA Therapeutics, the pioneer in RNA activation therapeutics, announced today the completion of a £23 million ($30 million) Series A equity financing led by aMoon, Israel’s largest healthtech and life sciences venture fund.

Read More

MOBILion Closes $35M Series B Financing Round

August 17, 2020

aMoon leads round to expand product portfolio and advance commercial efforts for MOBILion’s SLIM technology for biotherapeutics characterization and novel biomarker discovery

Read More

Roche invests millions in Israel’s health tech sector

August 11, 2020

has entered into a partnership agreement with aMoon, an Israeli venture capital company focused on health technology and science. The “StarFinder Lab” collaboration is aiming to help young startups develop innovative diagnostic tools to tackle global health care challenges.

Read More

Israel’s Largest Health VC Boosts Fund to $750 Million on Virus

July 22, 2020

Israel’s largest venture capital investor in life sciences, AMoon, boosted the size of its biggest fund to $750 million after demand for new health-care technology rose during the coronavirus pandemic.

Read More

Israeli healthtech VC aMoon Velocity invests $6 million in Nectin Therapeutics

July 15, 2020

Israel’s largest healthtech venture fund, aMoon, announced an investment of $6 million in Nectin Therapeutics Ltd. via its early-stage fund, aMoon Velocity.

Read More

Israel Bolsters Antibody Tests as Second Virus Wave Threatens

July 3, 2020

Israel is fortifying its national survey of exposure to the coronavirus as a second wave of infections threatens to plunge the country back into lockdown.

Read More